The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease

Background  Vorapaxar has been shown to reduce cardiovascular mortality in post-myocardial infarction (MI) patients. Pharmacodynamic biomarker research related to protease-activated receptor-1 (PAR-1) inhibition with vorapaxar in humans has short follow-up (FU) duration and is mainly focused on plat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsen, Dennis W. T., Røysland, Michelle, Ueland, Thor, Aukrust, Pål, Michelsen, Annika E., Staines, Harry, Barvik, Ståle, Kontny, Frederic, Nordrehaug, Jan Erik, Bonarjee, Vernon V. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113036/
https://www.ncbi.nlm.nih.gov/pubmed/36588289
http://dx.doi.org/10.1055/s-0042-1760256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113036/
https://www.ncbi.nlm.nih.gov/pubmed/36588289
http://dx.doi.org/10.1055/s-0042-1760256

Ejemplares similares